SEARCH RESULTS FOR:
Marc Lauzier
GENERAL MANAGER - PORCUPINE GOLD MINES, NEWMONT
Mining in Ontario and Toronto's Global Reach 2020
"Through the use of electric vehicles, we will be able to reduce 7,000 mt of greenhouse gas emissions and associated maintenance costs, as well as save the consumption of two million liters of diesel and one million liters of propane."
Sola Adepetun, Josephine Udonsak, Kayode Lawrence Omole, Rogba Payne
FOUNDING PARTNER AND SENIOR COUNSEL MEMBERS - ACAS-LAW
ACAS-Law is a leading corporate commercial law firm in Nigeria established in 1991 with extensive experience in the oil and gas industry.
Guillermo Crevatin
GENERAL MANAGER CHILE, BOLIVIA AND PERU, MICHELIN
Michelin Chile speaks of the advantages of its acquisition of Fenner and how it is developing its offering for the mining industry.
Edgardo Orderique
GENERAL MANAGER – OPERATIONS, MMG-LAS BAMBAS
MMG-Las Bambas discusses operational improvements, tailings management, and plans for the future.
Lekan Akinyanmi
CEO, LEKOIL
Lekoil is an Africa-focused oil exploration and production company with interests in Nigeria and offshore Namibia.
Jorge Buckup
PRESIDENT LATIN AMERICA, UNIVAR SOLUTIONS
Univar Solutions consolidates in the wider region through the Nexeo acquisition.
Christina Visser
GENERAL MANAGER, BLACK ROCK ENGINEERING
Black Rock Engineering is an engineering consulting company based in Sudbury, Ontario.
Ryan Matthiesen
MANAGING DIRECTOR – INVESTMENT BANKING, HAYWOOD SECURITIES
Haywood Securities is a full service investment bank that is predominantly resources focused.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
